Chernett Jorey has demonstrated a strong buying bias in recent months, with 24 purchases and only one sale across three companies—STIM, TOI, and AIRS—according to SEC Form 4 filings. The transactions, concentrated in March 2026, reveal a particular focus on STIM (Neuronetics, Inc.), where Jorey made multiple high-value purchases, including a $675,000 acquisition on March 27 and a $819,990 buy on March 18. TOI (The Oncology Institute) also saw significant investment, with purchases totaling $256,500 on March 17 and $767,960 on March 13. AIRS (AirSculpt Technologies) was another key holding, though activity here was mixed, including a single sale of $7,398.11 on March 23 alongside several buys, the largest being $257,210.64 on March 16.
Overall, Jorey’s trading activity reflects a clear accumulation strategy, with total buys exceeding $6.98 million against minimal sales of just $7,398. The largest transactions were in STIM, suggesting a concentrated position in the biotech firm, while TOI and AIRS saw smaller but still substantial investments. The pattern is consistent and directional, with no indication of profit-taking or diversification. Whether these moves reflect long-term conviction or other strategic considerations remains outside the scope of the data, but the filings underscore a decisive and nearly unilateral buying trend across these three holdings.
AI-assisted summary